3^rd Global Summit on Oncology & Cancer May 06-07, 2019 Tokyo, Japan

Biography:

Abstract:

Lung cancer remains the leading cause of cancer related deaths in most countries. Most (but not all) lung cancers are associated with tobacco smoking. Up until recent times, the diagnosis was in most cases based on histology and use of immunohistochemistry to classify lung epithelial tumors into small cell vs non- small cell (squamous and adeno) carcinomas. With the advent of better understanding of the biology of lung cancer, especially underlying oncogenic driver mutations, the hunt to develop targets to these mutations has increased manifold. This has led to the discovery of actionable mutations like EGFR, ALK and ROS-1. Current guidelines include testing for these driver mutations, aided primarily by clinical presentation and the histological subtype of tumor. There has also been a prominent focus on liquid biopsies in lung cancer given their innumerable advantages. We have thus witnessed a consequential change in the approach to treatment and survival of these patients. From an average survival of 2-4 months in 1990s, introduction of platinum-based combinations with third-generation agents and more specific cytotoxic drugs, significantly improved survival outcomes to 1-2 years. The newly developed targeted therapy in the appropriate patient population, may provide greater benefit than conventional chemotherapy and may further improve the survival rates in these patients.